Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
FRTX

FRTX - Fresh Tracks Therapeutics Inc Stock Price, Fair Value and News

$0.88-0.12 (-12.00%)
Market Closed

FRTX Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

FRTX Price Action

FRTX RSI Chart

FRTX Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

FRTX Valuation

FRTX Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

FRTX Fundamentals

FRTX Revenue

FRTX Earnings

FRTX Profitability

FRTX Investor Care

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20237.2M7.5M7.7M8.0M
20222.0M3.7M5.3M6.9M
20211.5M1.1M758.5K404.0K
20205.5M3.5M2.5M1.8M
20199.4M11.6M9.7M7.9M
201815.6M12.6M12.4M10.9M
201713.1M12.4M13.0M13.8M
201620.6M20.6M18.2M14.5M
201517.7M17.4M19.0M20.9M
20148.6M11.6M13.5M15.2M
20137.6M7.5M6.9M7.7M
201240.8M41.6M17.1M17.5M
20117.9M6.6M31.0M30.0M
2010011.4M10.0M8.7M
200900012.7M
Get all data in R, Python etc through our Historical Stock Data APIs

About Fresh Tracks Therapeutics Inc

FRTX
Fresh Tracks Therapeutics, Inc., a clinical-stage pharmaceutical company, engages in the development of various prescription therapeutics for the treatment of autoimmune, inflammatory, and other debilitating diseases in the United States. The company develops FRTX-02 (BBI-02), an oral DYRK1A inhibitor that is completed Phase 1 clinical trials for the treatment of autoimmune and inflammatory diseases; FRTX-10 (BBI-10), a covalent stimulator of interferon genes inhibitor for the potential treatment of autoinflammatory and rare genetic diseases; and FRTX-03, a topical DYRK1A inhibitor for the treatment of mild-to-moderate skin conditions, as well as next-generation kinase inhibitors. Fresh Tracks Therapeutics, Inc. has license and collaboration agreements with Carna Biosciences, Inc., and Voronoi Inc. The company was formerly known as Brickell Biotech, Inc. and changed its name to Fresh Tracks Therapeutics, Inc. in September 2022. Fresh Tracks Therapeutics, Inc. was founded in 2009 and is headquartered in Boulder, Colorado.
 CEO
 WEBSITEfrtx.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES13